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ABSTRACT
Objective To determine whether initial improvements in
obstructivesleepapnoeaafteraverylowenergydietwere
maintained after one year in patients with moderate to
severe obstructive sleep apnoea.
Design Single centre, prospective observational follow-
up study.
SettingOutpatientobesityclinicinauniversityhospitalin
Stockholm, Sweden.
Participants 63 men aged 30-65 with body mass index
(BMI) 30-40 and moderate to severe obstructive sleep
apnoea defined as an apnoea-hypopnoea index ≥15
(events/hour),alltreatedwithcontinuouspositiveairway
pressure.
Intervention A one year weight loss programme,
consisting of an initial very low energy diet for nine weeks
(seven weeks of 2.3 MJ/day and two weeks of gradual
introduction of normal food) followed by a weight loss
maintenance programme.
Main outcome measure Apnoea-hypopnoea index, the
main index for severity of obstructive sleep apnoea. Data
from all patients were analysed (baseline carried forward
for missing data).
ResultsOf63eligiblepatients,58completedtheverylow
energy diet period and started the weight maintenance
programme and 44 completed the full programme; 49
had complete measurements at one year. At baseline the
mean apnoea-hypopnoea index was 36 events/hour.
After the very low energy diet period, apnoea-hypopnoea
indexwasimprovedby−21events/hour(95%confidence
interval −17 to −25) and weight by −18 kg (−16 to −19;
both P<0.001). After one year the apnoea-hypopnoea
indexhadimprovedby −17events/hour(−13to −21)and
body weight by −12 kg (−10 to −14) compared with
baseline (both P<0.001). Patients with severe obstructive
sleep apnoea at baseline had greater improvements in
apnoea-hypopnoea index (−25 events/hour) compared
with patients with moderate disease (−7 events/hour,
P<0.001). At one year, 30/63 (48%, 95% confidence
interval 35% to 60%) no longer required continuous
positiveairwaypressureand6/63(10%,2%to17%)had
total remission of obstructive sleep apnoea (apnoea-
hypopnoea index <5 events/hour). There was a dose-
response association between weight loss and apnoea-
hypopnoea index at follow-up (β=0.50 events/kg, 0.11 to
0.88; P=0.013).
Conclusion Initial improvements in obstructive sleep
apnoea after treatment with a very low energy diet can be
maintained after one year in obese men with moderate to
severe disease. Those who lose the most weight or have
severe sleep apnoea at baseline benefit most.
Trial registration Current Controlled Trials 70090382.
INTRODUCTION
Obstructive sleep apnoea is common, underdiag-
nosed, and associated with negative health effects,
including impaired cognitive function, increased risk
for vehicle crashes and occupational injuries,
decreased quality of life, and increased mortality.
1-5
Of all people with obstructive sleep apnoea, an esti-
mated60-70%areeitheroverweightorobese.
67Given
thecloseassociationbetweenobstructivesleepapnoea
and obesity, weight loss has been advocated as a pri-
mary treatment option in obese patients with sleep
apnoea. Data from randomised controlled trials sup-
porting this concept were lacking until 2009, when
three trials on the effects of weight loss in obstructive
sleep apnoea were published.
8-10 Tuomilehto et al
investigated the effect of a very low energy diet fol-
lowed by supervised lifestyle counselling for one year
in overweight or obese patients with mild obstructive
sleep apnoea.
8 Foster et al investigated the effects of
intensive lifestyle changes in overweight or obese
patients with type 2 diabetes and mild to severe
obstructive sleep apnoea for one year.
9 Finally, we
investigated the effects of very low energy diet for
nine weeks in obese men with moderate to severe
obstructivesleepapnoea,
10theseverityofdiseaseasso-
ciated with an increased risk of mortality.
3411All three
trials found that weight loss resulted in clinically rele-
vant improvements in the apnoea-hypopnoea index,
themainindexforseverityofobstructivesleepapnoea.
Despite an improving case for the robust treatment
effect of weight loss in obstructive sleep apnoea,
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of improvements, especially after rapid weight loss
with a very low energy diet.
12 We evaluated the extent
to which initial improvements in the apnoea-hypop-
noea index (measured as events/hour) with very low
energy diet were maintained after one year in obese
patients with moderate to severe obstructive sleep
apnoea.
METHODS
The study was conducted at the Obesity Unit at Karo-
linskaUniversityHospital,KarolinskaInstitute,Stock-
holm, Sweden, between February 2009 and April
2010.
Participants
The current study is a one year pooled observational
follow-upofapreviouslypublishedrandomisedtrial.
10
We included men with moderate to severe obstructive
sleep apnoea (apnoea-hypopnoea index ≥15 events/
hour)treatedwithcontinuouspositiveairwaypressure
for a minimum of six months, aged 30-65, and with a
body mass index (BMI) of 30-40.
210
In the controlled trial, 63 patients were randomised
to intervention with very low energy diet or a control
group for nine weeks. After the randomised phase, the
control group crossed over to the same very low
energy diet programme as the intervention group.
After the very low energy diet period, both groups
entered a weight loss maintenance programme. The
results for the two groups were pooled for the current
analysis (fig 1).
Baseline was defined as the measurement before the
startoftheverylowenergydiet(fig1).Deviationsfrom
theinclusioncriteriaoftherandomisedcontrolledtrial
could therefore occur before crossover in patients ran-
domised to the control group. During the randomised
phasetheapnoea-hypopnoeaindexinonepatientallo-
catedtocontrolfellto14events/hour,andtwopatients
gained weight (to reach a BMI of 40.35 and 40.36).
Despite the deviation from the inclusion criteria of
the randomised controlled trial, we included these
patients in the analysis of the current follow-up study.
Intervention
Thefulltreatmentprogrammeofoneyearconsistedof
two periods: the very low energy diet period and the
weight loss maintenance period.
Very low energy diet period (0-9 weeks)
The very low energy diet weight loss programme con-
sisted of a standard 2.3 MJ/day liquid energy intake
protocol (Cambridge Weight Plan, Northants, UK)
forsevenweeks,followedbytwoweeks’gradualintro-
duction of normal food to reach 6.3 MJ/day at week
nine. To facilitate compliance with the programme,
patients were scheduled for six visits with clinical
examinations and group sessions.
10
Weight loss maintenance period (9-52 weeks)
The maintenance programme started immediately
after the very low energy diet period and was based
on standard behaviour modification group therapy
with a self help manual.
1314 The programme consisted
of three hour group therapy meetings every month.
Each group comprised 13-15 patients and was led by
aresearchnurseandadietitian.Inconjunctionwiththe
group sessions each patient was seen by a nurse for
anthropometry measurements and a dietitian for indi-
vidual dietary advice.
The behaviour modification focused on nutrition
education, eating behaviour, hunger and craving,
relapse situations, and increased physical activity.
Other important aspects were evaluation of progress
andidentificationofpersonalandenvironmentalinflu-
ences affecting eating and physical activity.
To prevent weight regain the protocol specified use
of partial meal replacement as a first option (exchan-
ging one or two daily meals with a 0.58 MJ meal repla-
cement, Cambridge Weight Plan, Northants, UK) if
the patient’s weight had increased by more than 2 kg
since the last visit (86% reported using partial meal
replacementatleastonce).Asasecondaryoptionsibu-
tramine or orlistat was prescribed (orlistat was pre-
scribed to only one patient).
Primary outcome
The primary outcome, the apnoea-hypopnoea index,
was measured at baseline and nine and 52 weeks. The
index is the total number of complete cessations of
breathing (apnoea) and partial obstructions (hypop-
noea) for at least 10 seconds during sleep.
15 The sever-
ity was defined according to the recommendations of
the American Academy of Sleep, who classify a fre-
quencyof5-14.9events/hourasmild,15-30asmoder-
ate,>30assevere,and<5asabsent.
15Inadditiontothe
apnoea-hypopnoea index, we recorded episodes of
oxygen desaturation ≥4%/hour of sleep, the nadir of
arterial oxygen saturation, and percentage of supine
time. Because of night to night variability of sleep
studies,
16 we derived sleep measurements from two
consecutive nocturnal sleep studies in the home,
using a six channel ambulatory polygraph (Watch
PAT100, Itamar Medical, Caesarea, Israel). We used
the Epworth sleepiness scale,
17 administered at
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Fig 1 | Design and treatment periods in obese men with moderate to severe sleep apnoea
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sleepiness. Further details of the sleep assessments can
be found elsewhere.
10
Atoneyear,theneedforcontinuouspositiveairway
pressure was evaluated at the sleep clinic. Continuous
positive airway pressure treatment was terminated if
subjective sleep quality and excessive daytime sleepi-
ness were normalised and the apnoea-hypopnoea
index was under 10.
Secondary outcomes
Secondary outcomes were body weight, waist and
neck circumference, percentage body fat, health
related quality of life, metabolic syndrome, hyperten-
sion, dyslipidaemia, and insulin resistance (the box
shows the definitions used). Metabolic variables were
measuredatbaselineandatnineand52weeksaccord-
ing to standard laboratory procedures. Health related
quality of life was measured with the SF-12 health sur-
vey (to allow quantification of a physical and a mental
component score
18) and compared with quality of life
data for the male Swedish population.
19
Anthropometry and body composition were mea-
suredatbaseline,afternineweeks,andmonthlyduring
the weight maintenance period. Percentage body fat
and body weight were measured with a Tanita BC-
418MA body fat analyser (Tanita Corporation of
America, Arlington Heights, IL).
23 Height was mea-
sured to the nearest cm with a wall mounted stadi-
ometer. BMI was calculated as weight (kg)/height
(m)
2. Waist circumference was measured in duplicate
halfway between the iliac crest and the lower rib cage
with patients standing in underwear. Neck circumfer-
ence was measured in duplicate at the level of the
superior border of the cricothyroid membrane.
Safety
Ateachvisitthestudynursenotedadverseeventsfrom
the very low energy diet, and subsequently the study
physician classified these events for potential causality
(unlikely/possibly/likely).Previouslyreportedadverse
events include dry mouth, diarrhoea, constipation,
headache,nausea/vomiting,dizziness,cramps,fatigue,
hunger, visual disturbance, feeling cold, hair loss, gall-
stones,andgout,allofwhichareconsideredtransient.
24
Statistical analysis
Datawere analysedwithStata version10(CollegeSta-
tion, TX) and SPSS (version 17.0, Chicago, IL). Mean
valuesandstandarddeviationswereusedunlessother-
wise stated. Medians and interquartile ranges were
used for variables with a skewed distribution.
We used paired samples t test to analyse changes
during the very low energy diet period (0-9 weeks),
the weight maintenance period (9-52 weeks), and the
full treatment programme (0-52 weeks), and
Definitions used in study
Metabolic syndrome was assessed in accordance with the unified definition of the
International Diabetes Federation (IDF) and the American Heart Association/National
Heart, Lung, and Blood Institute (AHA/NHLBI), joined by the World Heart Federation,
International Atherosclerosis Society, and International Association for the Study of
Obesity
20
Dyslipidaemia was defined as total cholesterol >5.0 mmol/L, low density lipoprotein
>3.0 mmol/L, high density lipoprotein <1.0 mmol/L, and triglycerides >1.7 mmol/L in
patients without cardiovascular disease and as total cholesterol >4.5 mmol/L and low
density lipoprotein >2.5 mmol/L in patients with cardiovascular disease or receiving drug
treatment, or both
Hypertension was defined as systolic/diastolic blood pressure of ≥140/90 mm Hg or
greater or receipt of antihypertensive drug treatment, or both
Insulin resistance was calculated with the homoeostasis model assessment (HOMA-IR)
(fasting plasma insulin (mU/L)×fasting plasma glucose (mmol/L)/22.5).
21 Insulin
resistance was defined as HOMA-IR ≥3.99
22
Table 1 |Baseline characteristics of obese men with
moderate to severe obstructive sleep apnoea
Mean(SD)or%
(No) (n=63) Range
Age (years) 48.7 (7.3) 33-61
Weight (kg) 113.1 (14.2) 86.9-139.9
Height (m) 1.80 (0.08) 1.65-2.03
Body mass index (BMI) 34.8 (2.9) 30.2-40.4
Waist circumference (cm) 120 (9) 101-139
Neck circumference (cm)* 44.9 (2.0) 39.3-49.0
Percentage body fat 31.0 (3.8) 21.9-40.4
Apnoea-hypopnoea index (events/hour)
Overall index 36 (15) 14-77
5-14.9 events/hour 2% (1) —
15-30 events/hour 41 % (26) —
>30 events/hour 57% (36) —
Apnoea-hypopnoea index (supine) 48 (20) 8-108
Oxygen desaturation ≥4%† 25 (14) 6-56
Oxygen desaturation ≥4%† (supine) 36 (20) 6-82
Lowest arterial oxygen saturation (%) 82 (5) 66-91
Supine time of sleep (%) 51 (24) 3-100
Epworth sleepiness scale* 8 (5) 0-23
Metabolic syndrome 70% (44) —
Blood pressure (mm Hg):
Systolic 131 (15) 108-179
Diastolic 83 (10) 63-112
Hypertension 57% (36) —
Triglycerides (mmol/L) 1.8 (1.0-2.2)‡ 0.5-8.6
Cholesterol (mmol/L):
Total 5.5 (0.9) 3.4-8.2
Low density lipoprotein 3.6 (0.8) 1.5-5.8
High density lipoprotein 1.1 (0.3) 0.6-2.1
Dyslipidaemia 94% (59) —
Fasting glucose (mmol/L) 5.7 (0.8) 4.3-9.5
Fasting insulin (mU/L) 14.0(9.6-21.6)‡ 3.0-49.0
HOMA-IR 3.5 (2.3-5.6)‡ 0.7-14.6
Insulin resistance 32% (20) —
Quality of life (SF-12)§:
Physical 46.5 (9.2) 26.7-61.4
Mental 52.9 (9.5) 27.5-69.1
HOMA-IR=homoeostasis model assessment-insulin resistance.
*n=60 because of missing data at baseline.
†Episodes/hour of sleep.
‡Median (interquartile range).
§n=59 because of missing data at baseline.
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apnoea-hypopnoea index between obstructive sleep
apnoea categories at baseline. Correlation and linear
regression analysis were used to evaluate predictors
of improvement in the apnoea-hypopnoea index and
to adjust for potential confounders.
Analyses included all randomised patients. We car-
ried forward baseline observations for missing data to
avoid overestimation associated with last observation
carried forward because of the rebound in weight that
usuallyoccursafterweightloss.Sensitivityanalysesfor
alternativeimputationtechniqueswerealsoperformed
with the last observation carried forward, multiple
imputation,andcompletersonlyanalysis.Formultiple
imputation,weusedageandbaselinevalueofthevari-
able of interest as explanatory variables. Analysis with
multiple imputation and completers should provide
similar estimates to the largest effect size, followed by
lastobservationcarriedforward,andendingwithbase-
line carried forward as the most conservative imputa-
tion approach.
Toreducetheamountofmissingdata,weinvitedthe
14 patients who discontinued treatment during weight
maintenance to attend the one year follow-up (see
appendix 1 on bmj.com). Ten of the 14 (71%) who
dropped out completed sleep measurements and six
(43%)completedadipositymeasurements.Imputation
was performed for the five patients who did not start
the maintenance programme and the patients who did
not attend the one year follow-up. We imputed sleep
values in nine and adiposity values in 13.
RESULTS
After crossing over to a very low energy diet, the
patients who had served as controls in the randomised
phase
10 achieved the same weight loss (−20 v −19 kg;
mean difference −1 kg, 95% confidence interval −3t o
1;P=0.34)andimprovementintheapnoea-hypopnoea
index(−21v−25events/hour;meandifference−4,−12
to 5; P=0.38) as the first intervention group. The find-
ing of greater improvements in patients with severe
versus moderate disease
10 was also replicated after
crossover of the controls (−26 v −13 events/hour,
P=0.02).
By pooling the two intervention groups, 58 of 63
patients completed the very low energy diet period
(two patients never started and three dropped out). At
oneyear49patientshadcompletedsleepandadiposity
follow-up measures, and 44 had completed the one
year treatment (see appendix 1 on bmj.com).
At baseline the majority of patients had severe
obstructive sleepapnoea, metabolicsyndrome, hyper-
tension, and dyslipidaemia (table 1, and 56%, 41%,
and3%hadaBMIof30-34.9,35-39.9,and≥40,respec-
tively. Those with moderate and severe obstructive
sleep apnoea had a mean apnoea-hypopnoea index of
23 and 46 events/hour, respectively. The physical
quality of life component (as measured with SF-12)
was lower than in the general male Swedish
population
19(47v51units,P<0.001),whilethemental
component was similar (53 v 54 units, P=0.57).
Changes in adiposity
Duringtheverylowenergydietandfulltreatmentpro-
gramme, weight, BMI, waist circumference, neck cir-
cumference, and percentage body fat all decreased
significantly, whereas all adiposity variables increased
significantly during the weight maintenance period
(table 2 and fig 2).
Of the 63 participants analysed at the one year fol-
low-up, one man (2%, 95% confidence interval −1% to
5%) was normal weight (BMI <25), 27 (43%, 31% to
55%) were overweight (BMI 25.0-29.9), and 35 (56%,
43% to 68%) remained obese (BMI ≥30).
Changes in obstructive sleep apnoea
All sleep variables, including the apnoea-hypopnoea
index,improvedsignificantlyaftertheverylowenergy
diet period and full treatment programme (table 3,
fig 3, and appendix 4 on bmj.com). During the weight
maintenanceperiod the apnoea-hypopnoea indexand
oxygen desaturation index increased significantly
(table 3; see appendix 2 on bmj.com for sensitivity
analyses with different imputation methods). At the
oneyearfollow-up,six (10%,95% confidenceinterval,
2% to 17%) had total remission of obstructive sleep
apnoea (apnoea-hypopnoea index <5), and 30 (48%,
35% to 60%) patients no longer required continuous
positive airway pressure, of whom 23 did not need
any further treatment with seven shifted to treatment
with an oral appliance (an orthodontic appliance worn
in the mouth during sleep that keeps airways free from
obstruction).
Improvements in the apnoea-hypopnoea index
were larger in men with severe obstructive sleep
apnoeaatbaselinethaninthosewithmoderatedisease
(−25 v −7 events/hour, P<0.001). Indeed, at one year
there was no difference in the apnoea-hypopnoea
index between patients who started with severe
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P=0.09; fig 4).
Dose-response of weight loss and change in obstructive
sleep apnoea
A dose-response relation existed between changes in
adiposity and apnoea-hypopnoea index: body weight
(r=0.41, P=0.004), waist circumference (r=0.40,
P=0.005), neck circumference (r=0.33, P=0.02), and
percentage body fat (r=0.40, P=0.004), fig 5.
Patientswholost≥15kghadlargerimprovementsin
the apnoea-hypopnoea index at oneyear than patients
who lost 10-14.9 kg (−30 v −15, P=0.004) or those who
lost <10 kg (−30 v −15, P=0.008).
After adjustment for baseline age, weight, apnoea-
hypopnoea index, and allocation (first or second very
low energy diet group), weight loss was significantly
associated with apnoea-hypopnoea index at follow-
up (β=0.50 events/kg, 0.11 to 0.88; P=0.013)—that is,
a 10 kg weight loss was associated with an average
decrease of 5 events/hour in the apnoea-hypopneoa
index at follow-up (see appendix 3 on bmj.com).
Patients who regained weight during the weight main-
tenance period had a significantly higher mean
apnoea-hypopnoea index at follow-up (β=0.48
events/kg, 0.08 to 0.87; P=0.02) after adjustment.
Quality of life
During the very low energy diet period, the physical
quality of life component increased by 5 units (3 to 7;
P<0.001),whilethementalcomponentwasunchanged
(2, −0.4 to 4; P=0.11) and remained similar to the level
in the general population.
19 Between baseline and one
year follow-up, the physical component score had
increased by 4 units (2 to 6; P<0.001) and was similar
to that in the general population (50 v 51; P=0.73).
Metabolic risk
Betweenbaselineandoneyearfollow-upallmetabolic
variables in table 1 improved significantly. Among
patients with metabolic disease at baseline, dyslipidae-
mia disappeared in 11/59 (19%, 9% to 29%), insulin
resistance in 10/20 (50%, 28% to 72%), and metabolic
syndrome in 23/44 (52%, 38% to 67%).
There were no differences in either systolic (−2m m
Hg,−6mmHgto2mmHg;P=0.36)ordiastolicblood
pressure (−1 mm Hg,−1 mm Hg to 3 mm Hg; P=0.48)
during the full treatment programme. Of those with
hypertension at baseline, however, it had disappeared
in 22% (8/36).
Table 2 |Changes in anthropometry (adiposity) after low energy diet and maintenance programme in 63 obese men with
moderate to severe sleep apnoea (baseline observation carried forward for missing data), with P values from paired sample
t test
After very low energy diet
(change 0-9 weeks)
Maintenance period
(change 9-52 weeks)
After full programme
(change 0-52 weeks)
Weight (kg)
Mean (SD) 95.4 (1.7) — 101.0 (14.6)
Mean (SD) change, 95% CI −17.7 (6.7), −16.0 to −19.4* 5.6 (7.6), 3.7 to 7.6* −12.1 (9.0), −9.8 to −14.3*
Mean (SD) % change −15.6 (5.4) 6.1 (7.9) −10.6 (7.3)
BMI
Mean (SD) 29.3 (2.9) — 31.1 (3.6)
Mean (SD) change, 95% CI −5.5 (2.0), −4.9 to −6.0* 1.8 (2.3), 1.2 to 2.4* −3.7 (2.7), −3.0 to −4.4*
Waist circumference (cm)
Mean (SD) 103.8 (9.5) — 107.0 (11.1)
Mean (SD) change, 95% CI −16.0 (6.6), −14.3 to −17.7* 3.2 (8.2), 1.2 to 5.3† −12.8 (8.5), −10.6 to −14.9*
Neck circumference (cm)‡ ‡
Mean (SD) 41.2 (2.1) — 42.4 (2.5)
Mean (SD) change, 95% CI −3.7 (1.7), −3.2 to −4.2* 1.2 (2.3), 0.7 to 1.7* −2.5 (1.6), −2.1 to −2.9*
Percentage body fat (%)
Mean (SD) 23.6 (5.9) — 27.1 (5.0)
Mean (SD) change, 95% CI −7.4 (3.4), −6.6 to −8.3* 3.5 (4.1), 2.5 to 4.6* −3.9 (3.7), −4.8 to −3.0*
*P<0.001.
†P=0.003.
‡n=60 because of missing data at baseline.
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Fig 3 | Proportions with obstructive sleep apnoea at baseline
and after treatment with very low energy diet and after one
year in 63 participants (baseline observation carried forward
for missing data). Apnoea-hypopnoea index: remission <5,
mild=5-14.9, moderate=15-30, severe obstructive sleep
apnoea >30 events/hour
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 5 of 9Adverse events
During the very low energy diet period 13/63 patients
(21%, 11% to 31%) had an adverse event classified as
probablycausallylinkedwiththeverylowenergydiet.
These adverse events were constipation (n=3),
increased alanine aminotransferase activity (n=6), diz-
ziness(n=1),gout(n=2), anddrylips(n=1).Alladverse
eventshaddisappearedbythevisittwoweeksafterthe
very low energy diet period.
During weight loss maintenance there were five
additional adverse events (5/58, 9%, 1% to 16%) prob-
ably causally linked to treatment with very low energy
diet (gallstones (n=3), gout (n=1), and kidney stones
(n=1)). No patient discontinued treatment because of
adverse events.
DISCUSSION
In this prospective observational study in obese men
with obstructive sleep apnoea, changes in the apnoea-
hypopnoeaindexafternineweeksofaverylowenergy
diet (−58%) were largely maintained at one year
(−47%). Patients with severe obstructive sleep apnoea
at baseline had larger improvements in the apnoea-
hypopnoea index than patients with moderate disease
(−25 v −7 events/hour). Moreover, we found a dose-
response association between weight loss and
improvement in the apnoea-hypopnoea index, with
patients who lost the most improving the most. At fol-
low-up, 30 (48%) men no longer required continuous
positive airway pressure, and six (10%) had total
remission of obstructive sleep apnoea. There were
also marked improvements in metabolic risk and the
physical dimension of quality of life, which no longer
differed from the level in the general population.
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Fig 4 | Association between apnoea-hypopnoea index at
baseline and follow-up for intention to treat population
(BOCF=baseline observation carried forward) and weight loss
categories in 63 participants. Dashed line represents cut off
for severe sleep apnoea (index >30 events/hour)
Table 3 |Changes in sleep variables after low energy diet and maintenance programme in 63 obese men with moderate to
severe sleep apnoea (baseline observation carried forward for missing data), with P values from paired sample t test
After very low energy diet
(change 0-9 weeks)
Maintenance period
(change 9-52 weeks)
After full programme
(change 0-52 weeks)
Apnoea-hypopnoea index
Mean (SD) 15 (9 ) — 19 (14)
Mean (SD) change, 95% CI −21 (16), −17 to −25* 4 (12), 1 to 7, P=0.007 −17 (16), −13 to −21*
Apnoea-hypopnoea index (supine)
Mean (SD) 25 (17) — 27 (18)
Mean (SD) change, 95% CI −23 (21), −18 to −29* 2 (19), −3t o7 ,P =0.41 −21 (3), −16 to −27*
Oxygen desaturation ≥ ≥4% (episodes/hour)
Mean (SD) 9 (7) — 12 (11)
Mean (SD) change, 95% CI −16 (13), −13 to −20* 3 (10), 1 to 6, P=0.01 −13 (13), −10 to −17*
Oxygen desaturation ≥ ≥4% (episodes/hour-supine)
Mean (SD) 17 (15) — 18 (17)
Mean (SD) change, 95% CI −19 (20), −14 to −24* 1 (17), −3t o6 ,P =0.49 −18 (20), −13 to −23*
Lowest arterial oxygen saturation (%)
Mean (SD) 86 (5) — 85 (5)
Mean (SD) change, 95% CI 4 (5), 3 to 5* −1( 4 ) ,−2t o0 . 2 ,P =0.10 3 (4), 2 to 4*
Supine time (%)
Mean (SD) 49 (24) — 54 (21)
Mean change, 95% CI −2 (22), −7t o4 ,P =0.56 5 (23), −1t o1 0 ,P =0.11 3 (24), −3t o9 ,P =0.32
Epworth sleepiness scale† †
Mean (SD) 5 (4) — 6( 5 )
Mean (SD) change, 95% CI −2( 4 ) ,−1t o−3* 1 (4), −0.3 to 2, P=0.18 −2( 3 ) ,−1t o−3*
*P<0.001.
†n=60 because of missing data at baseline.
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Randomisedcontrolledtrialshavepreviouslyshowna
positive effect of weight loss on obstructive sleep
apnoea. Tuomilehto et al found a 47% reduction in
the apnoea-hypopnoea index in patients with mild
obstructive sleep apnoea after a very low energy diet
(at 12 weeks), a 40% reduction with 11 kg weight loss
after one year, and a 46% reduction with a 7 kg weight
loss after two years.
825Foster et al found a 24% reduc-
tion in the apnoea-hypopnoea index after one year
with 11 kg weight loss after an intensive lifestyle inter-
vention in older (mean age 61) patients with type 2
diabetes,whiletheapnoea-hypopnoeaindexincreased
in controlpatients, resultingin a between group differ-
enceof42%.
9Finally,therandomisedpartofourstudy
documented a 67% reduction in the apnoea-hypop-
noea index after nine weeks after a mean weight loss
of 19 kg in middle aged men with moderate to severe
disease.
10 The dose-response association we found
between weight loss and the apnoea-hypopnoea
indexwasalsofoundbyFosteretal
9andTuomilehtoet
al
825andinourpreviousstudy.
10Fosteretalalsofound
significantly greater improvements in patients with
severe disease at baseline,
9 as in the current and our
previous study.
10
In addition to randomised controlled trials, two
uncontrolled studies,
2627 with smaller sample sizes
(n=24-33) and complete case analysis, have investi-
gated maintenance of initial improvements in obstruc-
tive sleep apnoea after a very low energy diet. Both
Lojander et al
26 and Kajaste et al
27 found that obstruc-
tive sleep apnoea was improved or largely maintained
after one year in patients completing the study.
Ourstudyextendspreviousfindingsbyhighlighting
the long term benefits of weight loss in people with
moderate and especially severe obstructive sleep
apnoea, which have both been associated with
increased mortality,
3411 in contrast with mild sleep
apnoea investigated previously by Tuomilehto et al.
825
In addition to dietary interventions, weight loss sur-
gery has also been shown to result in long term
improvements in obstructive sleep apnoea. In a large
study(n=3477) includingmatched controls,Grunstein
etalfoundthat30%ofthesurgerygroupreportedper-
sistent sleep apnoea at the two year follow-up com-
pared with 70% of the control group.
28 Small
uncontrolled studies (n<20) have also found long
term improvements in obstructive sleep apnoea after
weight loss surgery.
29-32
Clinical implications
According to previous studies, weight loss pro-
grammes should ideally achieve a weight loss of at
least 10-15 kg.
8925Very low energy diet treatment fol-
lowedbyaweightlossmaintenanceprogrammeisone
option for achieving long term weight loss of such
magnitude.
33 Three other studies have found that
improvements in obstructive sleep apnoea in other
patient groups were maintained one
89 and two years
after very low energy diet.
25
A very low energy diet is associated with some
adverse events, notably gallstones. There is no reason
to believe that these well known side effects occur dif-
ferently in patients with sleep apnoea than in obese
patients in general. The risk of adverse events, how-
ever, needs to be considered by clinicians and patients
before treatment is started.
Weightlosstrialstendtobeafflictedbyhighlevelsof
attrition with reported dropout levels of 30-39%.
34 In
the current study 30% (19/63) of participants did not
completethefulltreatmentprogramme,while14%(9/
63) were unavailable for the sleep study at follow-up.
Thecurrentstudythereforehasasimilarproportionof
patientsnotassessedatendofthestudyasinthestudies
by Tuomilehto et al (11%)
8 and Foster at al (17%).
9
Strengths and weaknesses
The strengths of the current study include the dupli-
catedsleepstudies,thefocusonpatientswithincreased
risk of mortality, and a design that allowed analysis of
whether initial improvements in obstructive sleep
apnoea can be maintained after rapid weight loss
induced by a very low energy diet.
The main limitation is the observational study
design. The reason for not using a randomised design
Measured data
BOCF for sleep and/or anthropometry data
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Fig 5 | Association between apnoea-hypopnoea index and
weight loss (kg). Top: relation between apnoea-hypopnoea
index and weight change in all 63 participants. Correlation
coefficient and regression line based only on those with
measured weight and index at baseline and follow-up (n=49).
Bottom: relation between apnoea-hypopnoea index and
weight for all participants with measured weight and index at
baseline and follow-up (n=49). Lines indicate individuals. No
participant gained weight, meaning that right-most
observation represents baseline value
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to show, in the short term, a treatment effect from
weight loss with a very low energy diet in moderate
to severe obstructive sleep apnoea. Our secondary
aim was to see whether any improvements could be
maintained in the long term. We therefore wanted to
minimise non-compliance in the control group in the
nine week randomised phase by providing a strong
incentive for controls to remain in the study by allow-
ing patients to start the very low energy diet pro-
gramme immediately after serving as controls.
The observational design means that our analysis is
limitedbythelackofcomparisonwithnaturalprogres-
sion in the apnoea-hypopnoea index and potential
regression to the mean. Without a control group, we
might have underestimated the one year treatment
effect, as Foster et al showed an increase in apnoea-
hypopnoea index in their control group over one
year.
9 The lack of control group also makes it difficult
to investigate if the larger reduction in the apnoea-
hypopnoea index in patients with severe rather than
moderate disease at baseline is a result of regression
to the mean rather than a true treatment effect. The
effect modification by baseline apnoea-hypopnoea
index, however, was seen both in the randomised
part of this study with the same population
10 and in
the study by Foster et al,
9 suggesting it is not purely
caused by regression to the mean.
Another limitation was the use of a portable Watch-
PAT device instead of a polysomnograph, whichis con-
sidered the ideal for diagnosing obstructive sleep
apnoea. The portable WatchPat does not technically
measureairflowbutquantifiesautonomicconsequences
ofdisorderedbreathingeventsduringsleepandisthere-
foreconsideredaclosesurrogatemeasureoftheapnoea-
hypopnoeaindexasdefinedby theAmericanAcademy
of Sleep.
15 Validation studies show that the WatchPAT
device has high sensitivity and specificity for pathologi-
cal respiratory disturbances, estimating sleep time and
apnoea-hypopnoea index accurately compared with
polysomnography.
3536
Finally, our results might not be generalisable to
women, younger (<30) or older (>65) patients,
overweight (BMI 25-29.9) or extremely obese patients
(BMI ≥40), or patients with mild sleep apnoea.
Conclusions
Improvements in apnoea-hypopnoea index after
weight loss induced by a very low energy diet were
largely maintained after one year, with patients with
severe obstructive sleep apnoea experiencing larger
reductions in the apnoea-hypopnoea index than
those with moderate disease at baseline. There was
also a dose-response association between weight loss
and improvement in the apnoea-hypopnoea index,
with patients who lost the most improving the most.
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